Jetema Co

Jetema Co FCF/Debt

The Free Cash Flow to Debt Ratio of Jetema Co (216080.KQ) as of Oct 23, 2026 is -9.58 %. In the previous year, Free Cash Flow to Debt Ratio was -4.26 % — a change of 124.72% (lower).

FCF/Debt

-9.58 %

YoY

124.72%

Last updated:

Free Cash Flow to Debt Ratio of Jetema Co is 2025 -9.58 % . Free Cash Flow to Debt Ratio of Jetema Co was 2024 -4.26 % . It decreases by 124.72% lower compared to the previous year.

The Jetema Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-100.08 KRW
Jan 1, 2019
-143.86 KRW
Jan 1, 2020
-9.60 KRW
Jan 1, 2021
-17.62 KRW
Jan 1, 2022
-46.38 KRW
Jan 1, 2023
-0.27 KRW
Jan 1, 2024
-4.26 KRW
Jan 1, 2025
-9.58 KRW
The Jetema Co FCF/Debt history
YEARFCF/DebtYoY
-9.58 %+124.72%
-4.26 %+1,500.48%
-0.27 %-99.43%
-46.38 %+163.17%
-17.62 %+83.59%
-9.60 %-93.33%
-143.86 %+43.74%
-100.08 %+14.89%
-87.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jetema Co Stock analysis

What does Jetema Co do? Jetema Co., Ltd. generates revenue through the manufacturing and distribution of aesthetic products such as dermal fillers, threads, botulinum toxin, and other medical devices. The company develops and sells hyaluronic acid fillers for facial beauty, medical devices for wrinkle, contour, and volume improvement, and laser equipment for treating leukoplakia, psoriasis, and alopecia areata. Additional products include the lifting medical device epiticons, cosmetic mask packs, and pharmaceutical excaine creams. The primary buyers are medical professionals and clinics seeking cosmetic and dermatological solutions. The company's product portfolio targets the aesthetic and medical device market segments, focusing on non-surgical beauty treatments and skin condition therapies. Jetema Co., Ltd. serves customers in the healthcare sector who require advanced medical devices for cosmetic procedures and dermatological care. The business model centers on direct sales of these specialized medical products to healthcare providers and clinics. Jetema Co., Ltd. operates with a workforce of 187 full-time employees based in Wonju, Gangwon-Do, and has been engaged in the development and manufacturing of hyaluronic acid fillers since its inception. The company's offerings are designed to address specific medical and cosmetic needs, with a focus on facial beauty and skin treatments. Revenue is derived from the sale of these medical devices and related products to healthcare professionals and clinics. Jetema Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jetema Co stock

Free Cash Flow to Debt Ratio of Jetema Co is -9.58 % in 2025.

Free Cash Flow to Debt Ratio of Jetema Co changed from -4.26 % to -9.58 %, representing a 124.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Jetema Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Jetema Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Jetema Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Jetema Co